Yigal Nochomovitz Recent News
Puma Biotech 'Is The Real Deal,' Overcomes Controversy With Positive FDA Panel Vote
Risk Confirmed: Ultragenyx Shares Downgraded To Sell By Citi
7 Binary Trades For The End Of 2016
The Street Is Getting The Ophthotech Story All Wrong
Here's Why Ophthotech Is Trading Down On Regeneron's News
Citi Sees 'Too Much Risk' In Portola Pharma, Downgrades To Neutral
Citi Downgrades Mirna Therapeutics To Neutral
Buy/High Risk Rating Given To Lexicon Pharmaceuticals By Citi Analysts
Galencia's Bid For Relypsa Is 'Reasonable,' Another Bidder 'Unlikely'
Medivation's Take-Out Price Raised To $68-$78 At Citi
Citi On Medivation-Sanofi Buyout Offer: More Bidders Likely Coming
Chimerix Downgraded By Citi's Nochomovitz, Kidney Transplant Play 'Isn't Panning Out'
Could Relypsa Be The Next Big Pharma Buyout Target?
8 Oppenheimer Analysts Choose Their Favorite Healthcare Stocks
Oppenheimer: Own Relypsa (Here's 14 Reasons)
UPDATE: Morgan Stanley Downgrades ImmunoGen Following Phase 2 Failure of IMGN901